Lexaria Bioscience Corp. (LEXX)

NASDAQ: LEXX · IEX Real-Time Price · USD
1.000
+0.030 (3.08%)
Sep 29, 2023, 4:00 PM EDT - Market closed
3.08%
Market Cap 8.09M
Revenue (ttm) 340,791
Net Income (ttm) -6.89M
Shares Out 8.09M
EPS (ttm) -1.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 50,196
Open 0.850
Previous Close 0.970
Day's Range 0.850 - 1.000
52-Week Range 0.649 - 3.595
Beta 1.14
Analysts Strong Buy
Price Target 2.00 (+100.02%)
Earnings Date Jul 14, 2023

About LEXX

Lexaria Bioscience Corp. operates as a biotechnology company. The company develops and out-licenses its DehydraTECH combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, ant... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 7
Stock Exchange NASDAQ
Ticker Symbol LEXX
Full Company Profile

Financial Performance

In 2022, LEXX's revenue was $255,397, a decrease of -64.66% compared to the previous year's $722,738. Losses were -$7.27 million, 80.5% more than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for LEXX stock is "Strong Buy" and the 12-month stock price forecast is $2.0.

Price Target
$2.0
(100.02% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Lexaria Announces Pricing of $1.6 Million Registered Direct Offering

KELOWNA, BC / ACCESSWIRE / September 29, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that i...

2 days ago - Accesswire

Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD

DehydraTECH-powered GLP-1 drugs will be evaluated for potential improvements such as: Reduced side effects; Enhanced weight loss; Improved health outcomes for diabetes and other conditions; Improved o...

10 days ago - Accesswire

Lexaria Provides Update on Investigational New Drug Application Progress

KELOWNA, BC / ACCESSWIRE / August 30, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is providing this update ...

4 weeks ago - Accesswire

Lexaria's DehydraTECH-Nicotine Faster than ZYN and on!

DehydraTECH-Nicotine reaches maximum blood saturation levels faster than world-leading brands from Swedish Match and Altria in human study NIC-H22-1 Noteworthy superior subjective performance characte...

7 weeks ago - Accesswire

Lexaria's Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD

KELOWNA, BC / ACCESSWIRE / August 2, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to report its in...

2 months ago - Accesswire

Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study

KELOWNA, BC / ACCESSWIRE / July 28, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has incorporate...

2 months ago - Accesswire

Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products

More countries are banning e-cigarettes as novel oral products gain traction KELOWNA, BC / ACCESSWIRE / July 19, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"...

2 months ago - Accesswire

Lexaria's Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science

DehydraTECH-CBD now featured in eight published, peer-reviewed papers KELOWNA, BC / ACCESSWIRE / June 22, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a gl...

3 months ago - Accesswire

Lexaria Receives New Patents

Total of 6 new granted patents received by Lexaria so far in 2023 Lexaria now holds 34 granted patents world-wide KELOWNA, BC / ACCESSWIRE / June 20, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASD...

3 months ago - Accesswire

Lexaria's DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study

Blood glucose levels reduced by 19.9% with DehydraTECH-CBD Improvements in kidney function also demonstrated KELOWNA, BC / ACCESSWIRE / June 16, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LE...

3 months ago - Accesswire

Lexaria Appoints New Chief Financial Officer

KELOWNA, BC / ACCESSWIRE / June 12, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of...

3 months ago - Accesswire

Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers

DehydraTECH-CBD offers distinctive mechanistic benefits related to its growing therapeutic utility KELOWNA, BC / ACCESSWIRE / May 23, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "...

4 months ago - Accesswire

Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery

900% and 2,000% improvements in peak bloodstream delivery using DehydraTECH KELOWNA, BC / ACCESSWIRE / May 18, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"),...

4 months ago - Accesswire

Lexaria Bioscience Announces Closing of $2.0 Million Public Offering

KELOWNA, BC / ACCESSWIRE / May 11, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing ...

5 months ago - Accesswire

cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial

DehydraTECH-CBD is currently unique in its evidenced superior power to reduce blood pressure over other oral CBD formulations. DehydraTECH-CBD has demonstrated exceptional safety and tolerability and ...

5 months ago - Accesswire

Lexaria Announces 2023 Annual Meeting Results

KELOWNA, BC / ACCESSWIRE / May 10, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the ...

5 months ago - Accesswire

Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering

KELOWNA, BC / ACCESSWIRE / May 8, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the pricing ...

5 months ago - Accesswire

Lexaria's Human Clinical Nicotine Study Completes Dosing as Planned

KELOWNA, BC / ACCESSWIRE / May 8, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that dosing of the t...

5 months ago - Accesswire

Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study

Clinical study will evaluate safety and tolerability of Lexaria's patented DehydraTECH-CBD as a potential treatment for hypertension California-based InClin to provide CRO services to manage and exped...

5 months ago - Accesswire

Lexaria is Receiving Four New Patents

KELOWNA, BC / ACCESSWIRE / April 20, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has recei...

5 months ago - Accesswire

Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels

KELOWNA, BC / ACCESSWIRE / March 2, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its diabetes...

7 months ago - Accesswire

Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4

KELOWNA, BC / ACCESSWIRE / February 21, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce...

7 months ago - Accesswire

Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor

KELOWNA, BC / ACCESSWIRE / January 23, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce th...

8 months ago - Accesswire

Lexaria Releases Annual Letter from the CEO

KELOWNA, BC / ACCESSWIRE / January 13, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide an...

9 months ago - Accesswire

Lexaria Receives First Granted Patent in Canada

KELOWNA, BC / ACCESSWIRE / December 29, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce i...

9 months ago - Accesswire